SG10201510106PA - Recombinant human naglu protein and uses thereof - Google Patents
Recombinant human naglu protein and uses thereofInfo
- Publication number
- SG10201510106PA SG10201510106PA SG10201510106PA SG10201510106PA SG10201510106PA SG 10201510106P A SG10201510106P A SG 10201510106PA SG 10201510106P A SG10201510106P A SG 10201510106PA SG 10201510106P A SG10201510106P A SG 10201510106PA SG 10201510106P A SG10201510106P A SG 10201510106PA
- Authority
- SG
- Singapore
- Prior art keywords
- recombinant human
- naglu protein
- human naglu
- protein
- recombinant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2474—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161546248P | 2011-10-12 | 2011-10-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201510106PA true SG10201510106PA (en) | 2016-01-28 |
Family
ID=48082738
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201510106PA SG10201510106PA (en) | 2011-10-12 | 2012-10-11 | Recombinant human naglu protein and uses thereof |
| SG11201401457SA SG11201401457SA (en) | 2011-10-12 | 2012-10-11 | Recombinant human naglu protein and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201401457SA SG11201401457SA (en) | 2011-10-12 | 2012-10-11 | Recombinant human naglu protein and uses thereof |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20140255383A1 (en) |
| EP (1) | EP2766477B1 (en) |
| JP (1) | JP6329483B2 (en) |
| KR (1) | KR20140108519A (en) |
| CN (1) | CN103958676A (en) |
| AU (1) | AU2012322811A1 (en) |
| BR (1) | BR112014008873A2 (en) |
| CA (1) | CA2852027A1 (en) |
| CL (1) | CL2014000927A1 (en) |
| CO (1) | CO7010783A2 (en) |
| HK (1) | HK1200489A1 (en) |
| IL (1) | IL232073A0 (en) |
| IN (1) | IN2014MN00740A (en) |
| MX (1) | MX2014004359A (en) |
| RU (1) | RU2014117291A (en) |
| SG (2) | SG10201510106PA (en) |
| TW (1) | TW201321515A (en) |
| WO (1) | WO2013055888A2 (en) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008022349A2 (en) | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| US8974791B2 (en) | 2007-07-27 | 2015-03-10 | Armagen Technologies, Inc. | Methods and compositions for increasing α-L-iduronidase activity in the CNS |
| EP2485761B1 (en) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| AU2011314293B2 (en) | 2010-09-09 | 2015-06-04 | Alexion Pharmaceuticals, Inc. | Use of Lysosomal Acid Lipase for treating Lysosomal Acid Lipase Deficiency in patients |
| KR20140006037A (en) | 2011-02-15 | 2014-01-15 | 시나게바 바이오파르마, 코포레이션 | Methods for treating lysosomal acid lipase deficiency |
| JP6329483B2 (en) * | 2011-10-12 | 2018-05-23 | シナジェバ・バイオファーマ・コーポレイションＳｙｎａｇｅｖａ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐ． | Recombinant human NAGLU protein and use thereof |
| EP3711778A1 (en) | 2011-12-02 | 2020-09-23 | Armagen, Inc. | Methods and compositions for increasing arylsulfatase a activity in the cns |
| MX2015015560A (en) * | 2013-05-15 | 2016-06-17 | Univ Minnesota | Adeno-associated virus mediated gene transfer to the central nervous system. |
| TWI793159B (en) * | 2013-10-23 | 2023-02-21 | 美商健臻公司 | Recombinant glycoproteins and uses thereof |
| UA123985C2 (en) * | 2014-05-14 | 2021-07-07 | Лабораторіос Дель Др. Естеве С.А. | Adenoassociated virus vectors for the treatment of lysosomal storage disorders |
| US20170267986A1 (en) * | 2014-06-25 | 2017-09-21 | Shire Human Genetic Therapies, Inc. | Generation of mannose-6-phosphate containing recombinant alpha-n-acetyl glucosaminidase |
| BR112017002741A2 (en) | 2014-08-11 | 2018-02-27 | Shire Human Genetic Therapies, Inc | mannose-6-phosphate containing peptides fused to lysosomal enzymes |
| EP3200816A1 (en) | 2014-09-29 | 2017-08-09 | Alexion Pharmaceuticals, Inc. | Methods of treating mucopolysaccharidosis iiib (mpsiiib) |
| CN104524662B (en) * | 2014-12-31 | 2017-02-22 | 迈得医疗工业设备股份有限公司 | Feeding mechanism for medical needle base assembling |
| US10538589B2 (en) * | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| WO2017132675A1 (en) * | 2016-01-29 | 2017-08-03 | Alexion Pharmaceuticals, Inc. | Enzyme replacement therapy in mucopolysaccharidosis iiib patients |
| EP3452104A1 (en) | 2016-04-15 | 2019-03-13 | The Trustees of The University of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
| US10633705B2 (en) | 2016-10-14 | 2020-04-28 | Alexion Pharmaceuticals, Inc. | N-acetyl-alpha-D-glucosaminidase deficiency compositions and methods |
| US11819539B2 (en) | 2017-09-22 | 2023-11-21 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating Mucopolysaccharidosis type II |
| EP3692070A1 (en) | 2017-10-02 | 2020-08-12 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| US20230149564A1 (en) * | 2020-03-23 | 2023-05-18 | The University Of North Carolina At Chapel Hill | Aav-naglu vectors for treatment of mucopolysaccharidosis iiib |
| CN111718947B (en) * | 2020-06-18 | 2022-08-23 | 舒泰神（北京）生物制药股份有限公司 | Adeno-associated virus vector for treating type IIIA or IIIB mucopolysaccharidosis and use thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6825396B2 (en) | 1996-06-12 | 2004-11-30 | Board Of Trustees Operating Michigan State University | Methods for tissue specific synthesis of protein in eggs of transgenic hens |
| US5897998A (en) | 1997-08-04 | 1999-04-27 | The University Of Georgia Research Foundation, Inc. | Method for manipulating avian eggs |
| AU752946B2 (en) | 1997-10-16 | 2002-10-03 | Avigenics, Inc. | Vectors comprising a magnum-specific promoter for avian transgenesis |
| US7511120B2 (en) | 1997-10-16 | 2009-03-31 | Synageva Biopharma Corp. | Glycosylated G-CSF obtained from a transgenic chicken |
| US20040019923A1 (en) | 1997-10-16 | 2004-01-29 | Ivarie Robert D. | Exogenous proteins expressed in avians and their eggs |
| US6217552B1 (en) | 1999-03-01 | 2001-04-17 | Coaxia, Inc. | Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma |
| US6537785B1 (en) * | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
| US7138262B1 (en) | 2000-08-18 | 2006-11-21 | Shire Human Genetic Therapies, Inc. | High mannose proteins and methods of making high mannose proteins |
| US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| US6875588B2 (en) | 2001-11-30 | 2005-04-05 | Avigenics, Inc. | Ovomucoid promoter and methods of use |
| US7294507B2 (en) | 2001-11-30 | 2007-11-13 | Avigenics, Inc. | Ovomucoid promoters and methods of use |
| US6679165B2 (en) | 2002-05-22 | 2004-01-20 | Shiny Shih | Window adapted to a dater |
| US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| EP1587923B1 (en) * | 2003-01-22 | 2011-08-24 | Duke University | Improved constructs for expressing lysosomal polypeptides |
| US7442372B2 (en) * | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050090001A1 (en) | 2003-10-07 | 2005-04-28 | Parker Stephen H. | Cell lines and methods for producing proteins |
| US20050208090A1 (en) * | 2004-03-18 | 2005-09-22 | Medtronic, Inc. | Methods and systems for treatment of neurological diseases of the central nervous system |
| EP1746902A4 (en) * | 2004-05-05 | 2007-06-13 | Univ Northeastern | Multi-lectin affinity chromatography and uses thereof |
| CA2641070C (en) | 2006-02-06 | 2017-01-03 | Ramot At Tel-Aviv University Ltd. | Enzyme replacement therapy for treating lysosomal storage diseases |
| CN101410408A (en) | 2006-04-04 | 2009-04-15 | 希尔制药爱尔兰有限责任公司 | A process for concentration of a polypeptide |
| CA2671570A1 (en) | 2007-01-26 | 2008-07-31 | Synageva Biopharma Corp. | Transgene expression in avians |
| BRPI0907239A2 (en) * | 2008-01-07 | 2017-06-13 | Synageva Biopharma Corp | methods for isolating a protein and for producing an aprotein in a poultry house |
| WO2009131698A2 (en) * | 2008-04-23 | 2009-10-29 | Iowa State University Research Foundation, Inc. | PHOSPHORYLATED RECOMBINANT N-ACETYL-alpha-D- GLUCOSAMINIDASE (NaGlu) AND USES THEREOF |
| CA2766614C (en) * | 2009-07-03 | 2018-06-19 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
| NZ702801A (en) | 2010-06-25 | 2016-08-26 | Shire Human Genetic Therapies | Treatment of sanfilippo syndrome type b |
| EP3875107A1 (en) * | 2010-06-25 | 2021-09-08 | Shire Human Genetic Therapies, Inc. | Pharmaceutical formulation comprising a replacement enzyme for a lysosomal enzyme for use in treating lysosomal storage disease intrathecally |
| WO2012012742A2 (en) * | 2010-07-22 | 2012-01-26 | Shire Human Genetic Therapies, Inc. | Crystal structure of human alpha-n-acetylglucosaminidase |
| AU2011314293B2 (en) | 2010-09-09 | 2015-06-04 | Alexion Pharmaceuticals, Inc. | Use of Lysosomal Acid Lipase for treating Lysosomal Acid Lipase Deficiency in patients |
| JP6329483B2 (en) * | 2011-10-12 | 2018-05-23 | シナジェバ・バイオファーマ・コーポレイションＳｙｎａｇｅｖａ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐ． | Recombinant human NAGLU protein and use thereof |
-
2012
- 2012-10-11 JP JP2014535865A patent/JP6329483B2/en active Active
- 2012-10-11 US US14/350,644 patent/US20140255383A1/en not_active Abandoned
- 2012-10-11 US US13/649,595 patent/US9579366B2/en active Active
- 2012-10-11 EP EP12840612.1A patent/EP2766477B1/en active Active
- 2012-10-11 CN CN201280049876.4A patent/CN103958676A/en active Pending
- 2012-10-11 SG SG10201510106PA patent/SG10201510106PA/en unknown
- 2012-10-11 RU RU2014117291/10A patent/RU2014117291A/en not_active Application Discontinuation
- 2012-10-11 SG SG11201401457SA patent/SG11201401457SA/en unknown
- 2012-10-11 CA CA2852027A patent/CA2852027A1/en not_active Abandoned
- 2012-10-11 AU AU2012322811A patent/AU2012322811A1/en not_active Abandoned
- 2012-10-11 IN IN740MUN2014 patent/IN2014MN00740A/en unknown
- 2012-10-11 WO PCT/US2012/059708 patent/WO2013055888A2/en active Application Filing
- 2012-10-11 KR KR1020147012617A patent/KR20140108519A/en not_active Application Discontinuation
- 2012-10-11 BR BR112014008873-0A patent/BR112014008873A2/en not_active Application Discontinuation
- 2012-10-11 MX MX2014004359A patent/MX2014004359A/en unknown
- 2012-10-12 TW TW101137865A patent/TW201321515A/en unknown
-
2014
- 2014-04-10 IL IL232073A patent/IL232073A0/en unknown
- 2014-04-11 CL CL2014000927A patent/CL2014000927A1/en unknown
- 2014-05-08 CO CO14098853A patent/CO7010783A2/en unknown
-
2015
- 2015-01-27 HK HK15100907.5A patent/HK1200489A1/en unknown
-
2017
- 2017-02-10 US US15/429,309 patent/US20170216412A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CL2014000927A1 (en) | 2014-11-14 |
| HK1200489A1 (en) | 2015-08-07 |
| CO7010783A2 (en) | 2014-07-31 |
| WO2013055888A3 (en) | 2013-06-13 |
| US9579366B2 (en) | 2017-02-28 |
| IN2014MN00740A (en) | 2015-05-22 |
| JP2014534962A (en) | 2014-12-25 |
| US20140255383A1 (en) | 2014-09-11 |
| NZ623690A (en) | 2016-08-26 |
| EP2766477A2 (en) | 2014-08-20 |
| KR20140108519A (en) | 2014-09-11 |
| CN103958676A (en) | 2014-07-30 |
| US20130095092A1 (en) | 2013-04-18 |
| WO2013055888A2 (en) | 2013-04-18 |
| RU2014117291A (en) | 2015-11-20 |
| MX2014004359A (en) | 2014-05-28 |
| TW201321515A (en) | 2013-06-01 |
| SG11201401457SA (en) | 2014-05-29 |
| CA2852027A1 (en) | 2013-04-18 |
| EP2766477A4 (en) | 2015-07-15 |
| US20170216412A1 (en) | 2017-08-03 |
| JP6329483B2 (en) | 2018-05-23 |
| BR112014008873A2 (en) | 2020-09-15 |
| AU2012322811A1 (en) | 2014-05-01 |
| IL232073A0 (en) | 2014-05-28 |
| EP2766477B1 (en) | 2018-09-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1200489A1 (en) | Recombinant human naglu protein and uses thereof naglu | |
| IL260045B (en) | Polypeptide constructs and uses thereof | |
| IL279676A (en) | Recombinant proteins and their therapeutic uses | |
| IL230918A0 (en) | Modified proteins and peptides | |
| EP2593469A4 (en) | Modified polypeptides and proteins and uses thereof | |
| IL230120B (en) | Compositions comprising recombinant human iduronate-2-sulfatase and uses thereof | |
| IL229723A0 (en) | Human fusion proteins comprising interferons and trageted modified ubiquitin proteins | |
| ZA201307641B (en) | Human tissue factor antibody and uses thereof | |
| EP2799540A4 (en) | Human arginase and pegylated human arginase and application thereof | |
| PL2588491T3 (en) | Novel peptide and use thereof | |
| EP2738255A4 (en) | Erap1-derived peptide and use thereof | |
| PL2668205T3 (en) | Human lactoferrin derived peptides and their use | |
| EP2711376A4 (en) | Fgfr-fc fusion protein and use thereof | |
| SG10201507721SA (en) | CHO-GMT Recombinant Protein Expression | |
| EP2734543A4 (en) | Lactoferrin fragments and use thereof | |
| EP2930183A4 (en) | Recombinant protein and uses thereof in the diagnosis of multiple sclerosis | |
| EP2918600A4 (en) | Novel peptide and use thereof | |
| HK1211952A1 (en) | Recombinant protein | |
| IL230474A0 (en) | Lactoferrin fragments and use thereof | |
| GB201121233D0 (en) | Modified proteins and peptides | |
| GB201121226D0 (en) | Modified proteins and peptides | |
| GB201121236D0 (en) | Proteins and peptides |